控释胰岛素样生长因子1微珠改善大鼠尿道括约肌功能与组织结构的女性压力性尿失禁治疗研究
研究在大鼠压力性尿失禁模型中,经尿道周围注射控释IGF-1的藻酸盐-聚-L-鸟氨酸-明胶微珠,评估其对尿道外括约肌组织再生的影响。结果显示,注射IGF-1微珠1周后漏点压显著高于空微珠组,与假手术组无显著差异,组织学可见骨骼肌纤维排列有序和血管形成。作者认为该疗法有前景,但需在动物模型和人体中进行更详细、更长期的研究。
要点
- VD+IGF-1微珠组1周漏点压28.4 cmH2O,显著高于VD+空微珠组21.7 cmH2O。
- VD+盐水组和VD+空微珠组漏点压显著低于假手术组44.4 cmH2O。
- IGF-1微珠组组织学显示骨骼肌纤维排列有序和血管形成,优于对照。
核心结论
- 尿道周围注射IGF-1-A-PLO-G微珠通过促进骨骼肌生成和血管再生促进压力性尿失禁恢复。
- 作者认为该疗法有前景,但需在动物模型和人体中进行更详细、更长期的研究。
研究设计与样本
- 研究将44只雌性Sprague-Dawley大鼠随机分为四组:阴道扩张后尿道周围注射IGF-1-A-PLO-G微珠(VD+IGF-1微珠;1×10^4微珠/1 mL生理盐水)、VD+空微珠、VD+生理盐水、假手术VD+生理盐水。
主要发现
- VD+生理盐水组1周漏点压均值(标准误)为23.9(1.3)cmH2O,VD+空微珠组为21.7(0.8)cmH2O,均显著低于假手术组44.4(3.4)cmH2O(P<0.05),提示微珠本身不产生尿道填充或梗阻效应。
- VD+IGF-1微珠组1周漏点压均值(标准误)为28.4(1.2)cmH2O,显著高于VD+空微珠组(P<0.05),与假手术组无显著差异,提示VD后1周即出现修复效应。
- 组织学分析显示,VD+IGF-1微珠组1周时尿道外括约肌可见排列有序的骨骼肌纤维和血管发育,而VD+生理盐水组或VD+空微珠组1周时可见明显肌纤维萎缩、排列紊乱和血管形成减少。
关键数值与推荐
- 漏点压(LPP)为尿道功能评价指标:VD+IGF-1微珠组28.4(1.2)cmH2O vs VD+空微珠组21.7(0.8)cmH2O(P<0.05)。
- VD+生理盐水组23.9(1.3)cmH2O和VD+空微珠组21.7(0.8)cmH2O均显著低于假手术组44.4(3.4)cmH2O(P<0.05)。
- VD+IGF-1微珠组漏点压与假手术组无显著差异。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出该疗法有前景,但需要在动物模型和人体中进行更详细、更长期的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the effects of controlled release of insulin-like growth factor 1 (IGF-1) from alginate-poly-L-ornithine-gelatine (A-PLO-G) microbeads on external urethral sphincter (EUS) tissue regeneration in a rat model of stress urinary incontinence (SUI), as SUI diminishes the quality of life of millions, particularly women who have delivered vaginally, which can injure the urethral sphincter. Despite several well-established treatments for SUI, growth factor therapy might provide an alternative to promote urethral sphincter repair. MATERIALS AND METHODS: In all, 44 female Sprague-Dawley rats were randomised into four groups: vaginal distension (VD) followed by periurethral injection of IGF-1-A-PLO-G microbeads (VD + IGF-1 microbeads; 1 × 104 microbeads/1 mL normal saline); VD + empty microbeads; VD + saline; or sham-VD + saline (sham). RESULTS: Urethral function (leak-point pressure, LPP) was significantly lesser 1 week after VD + saline [mean (sem) 23.9 (1.3) cmH2 O] or VD + empty microbeads [mean (sem) 21.7 (0.8) cmH2 O) compared to the sham group [mean (sem) 44.4 (3.4) cmH2 O; P < 0.05), indicating that the microbeads themselves do not create a bulking or obstructive effect in the urethra. The LPP was significantly higher 1 week after VD + IGF-1 microbeads [mean (sem) 28.4 (1.2) cmH2 O] compared to VD + empty microbeads (P < 0.05), and was not significantly different from the LPP in sham rats, demonstrating an initiation of a reparative effect even at 1 week after VD. Histological analysis showed well-organised skeletal muscle fibres and vascular development in the EUS at 1 week after VD + IGF-1 microbeads, compared to substantial muscle fibre attenuation and disorganisation, and less vascular formation at 1 week after VD + saline or VD + empty microbeads. CONCLUSION: Periurethral administration of IGF-1-A-PLO-G microbeads facilitates recovery from SUI by promoting skeletal myogenesis and revascularisation. This therapy is promising, but detailed and longer term studies in animal models and humans are needed.
引用
- Yan H, Zhong L, Jiang Y, et al. Controlled release of insulin-like growth factor 1 enhances urethral sphincter function and histological structure in the treatment of female stress urinary incontinence in a rat model. BJU Int. 2017. PMID: 28805303. doi:10.1111/bju.13985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。